logo-loader
CelLBxHealth PLC

CelLBxHealth PLC - Confirmation of Q1 trading update

RNS Number : 4838C
CelLBxHealth PLC
30 April 2026
 

 

CelLBxHealth plc

 ("CelLBxHealth" or "the Company")

 

Confirmation of Q1 trading update

 

Guildford, UK and Plymouth Meeting, U.S. - 30 April 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology, announces that it will provide a trading update for Q1 2026 in mid-May.

 

For further information:

 

CelLBxHealth plc

Peter Collins, Chief Executive Officer

Jan Groen, Executive Chairman

investor@cellbxhealth.com

via Walbrook PR 

 


Cavendish (NOMAD and Broker)

Geoff Nash / Isaac Hooper (Corporate Finance)

Sunila de Silva (Corporate Broking)

Nigel Birks (Life Science Specialist Sales)

+44 (0)20 7220 0500 

 

 


Walbrook PR (Investor and Media Relations)

Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® Platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

 

Commercial focus span three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through a combination of strategic partnerships and in-house development.

 

For more information, visit https://cellbxhealth.com/.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAFLNAAFKEAA
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE

Gelion, CelLBxHealth, Ashtead Technology, Rainbow Rare Earths, Bradda Head...

Gelion PLC (AIM:GELN, OTC:GELNF) shares rose over 12% to 18p after it reported £9.6 million of pro forma cash and no debt. Releasing full-year results, it noted agreements with two major automakers, and the CEO says it’s moving from validation towards customer programmes and scale-up. Read...

4 weeks, 1 day ago

2 min read